Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2016', provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL) - The report reviews pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Peripheral T-Cell Lymphomas (PTCL) therapeutics and enlists all their major and minor projects - The report assesses Peripheral T-Cell Lymphomas (PTCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Peripheral T-Cell Lymphomas (PTCL) Overview 9 Therapeutics Development 10 Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Overview 10 Peripheral T-Cell Lymphomas (PTCL) - Therapeutics under Development by Companies 11 Peripheral T-Cell Lymphomas (PTCL) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Peripheral T-Cell Lymphomas (PTCL) - Products under Development by Companies 16 Peripheral T-Cell Lymphomas (PTCL) - Companies Involved in Therapeutics Development 18 AB Science SA 18 Affimed Therapeutics AG 19 Bayer AG 20 Celgene Corporation 21 CerRx, Inc. 22 Chipscreen Biosciences Ltd 23 Eisai Co., Ltd. 24 Incyte Corporation 25 Johnson & Johnson 26 Karyopharm Therapeutics, Inc. 27 Mundipharma International Ltd 28 Ono Pharmaceutical Co., Ltd. 29 Onxeo SA 30 Pfizer Inc. 31 Rhizen Pharmaceuticals S.A. 32 Seattle Genetics, Inc. 33 Solasia Pharma K.K. 34 Spectrum Pharmaceuticals, Inc. 35 TG Therapeutics, Inc. 36 Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Target 38 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 AFM-13 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 belinostat - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 brentuximab vedotin - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 copanlisib hydrochloride - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 CS-055 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 darinaparsin - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 denileukin diftitox - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 fenretinide - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 forodesine hydrochloride - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 lenalidomide - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 masitinib - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 mitoxantrone hydrochloride - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 nivolumab - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 NL-101 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 pralatrexate - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 romidepsin - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 RP-6530 - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 ruxolitinib phosphate - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 selinexor - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 SH-7129 - Drug Profile 114 Product Description 114 Mechanism of Action 114 R&D Progress 114 temsirolimus - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 TGR-1202 - Drug Profile 118 Product Description 118 Mechanism of Action 118 R&D Progress 118 tipifarnib - Drug Profile 121 Product Description 121 Mechanism of Action 121 R&D Progress 121 Peripheral T-Cell Lymphomas (PTCL) - Recent Pipeline Updates 124 Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects 213 Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products 214 Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones 215 Featured News & Press Releases 215 Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 215 Dec 07, 2015: Seattle Genetics Highlights ADCETRIS Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015 215 Dec 06, 2015: Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP 217 Nov 09, 2015: Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma 218 Sep 30, 2015: Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma 220 Jun 23, 2015: Beleodaq (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology 220 May 27, 2015: AB Science: Phase 2 with masitinib in peripheral T-cell lymphoma accelerated into phase 3 221 Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China 223 Dec 09, 2014: Combination of ISTODAX (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of Patients with Peripheral T-Cell Lymphoma 223 Dec 05, 2014: Spectrum Pharmaceuticals Highlights Abstracts on Beleodaq (belinostat) at the 56th Annual Meeting of the ASH in San Francisco 224 Appendix 225 Methodology 225 Coverage 225 Secondary Research 225 Primary Research 225 Expert Panel Validation 225 Contact Us 225 Disclaimer 226
List of Tables
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2016 10 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Development by Companies, H1 2016 (Contd..1) 17 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by AB Science SA, H1 2016 18 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Affimed Therapeutics AG, H1 2016 19 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Bayer AG, H1 2016 20 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Celgene Corporation, H1 2016 21 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CerRx, Inc., H1 2016 22 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Chipscreen Biosciences Ltd, H1 2016 23 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Eisai Co., Ltd., H1 2016 24 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Incyte Corporation, H1 2016 25 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Johnson & Johnson, H1 2016 26 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 27 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Mundipharma International Ltd, H1 2016 28 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 29 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Onxeo SA, H1 2016 30 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pfizer Inc., H1 2016 31 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 32 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Seattle Genetics, Inc., H1 2016 33 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Solasia Pharma K.K., H1 2016 34 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 35 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by TG Therapeutics, Inc., H1 2016 36 Assessment by Monotherapy Products, H1 2016 37 Number of Products by Stage and Target, H1 2016 39 Number of Products by Stage and Mechanism of Action, H1 2016 42 Number of Products by Stage and Route of Administration, H1 2016 44 Number of Products by Stage and Molecule Type, H1 2016 46 Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Recent Pipeline Updates, H1 2016 124 Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects, H1 2016 213 Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products, H1 2016 214
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.